Pharmaceuticals - Spotlight on non-US centric players
In the past two years US-centric players have seen dramatic erosion in
base business on account of, by now, familiar reasons of steep fall in generic prices fueled by buyer consolidation, accelerated FDA
approvals and persistent regulatory woes.
Read more